Aliskiren, the future of renin-angiotensin system blockade?


ÜRESİN A. Y., Bozkurt M. M., SABIRLI S., Ozunal Z.

Expert Review of Cardiovascular Therapy, cilt.5, sa.5, ss.835-849, 2007 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 5 Sayı: 5
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1586/14779072.5.5.835
  • Dergi Adı: Expert Review of Cardiovascular Therapy
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.835-849
  • Anahtar Kelimeler: Aangiotensin-converting enzyme inhibitors, Aliskiren, Angiotensin receptor blockers, Hypertension, Oral renin inhibitors, Renin-angiotensin-aldosterone system
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

The suppression of the renin-angiotensin system by angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been proven in many studies to treat hypertension and reduce cardiovascular events; however, reducing angiotensin I receptor stimulation results in the loss of the negative-feedback signal, leading to increased plasma renin activity. Numerous direct renin inhibitors were synthesized, but abandoned owing to low potency, poor bioavailability and short half-life. Aliskiren, a direct renin inhibitor of a novel structural class, inhibits the activity of the renin produced and, thus, its capacity to form angiotensin I, as measured by plasma renin activity. Aliskiren has been recently shown to be efficacious in hypertensive patients at once-daily oral dosing with favorable pharmacokinetics and the potential to improve end-organ protection. © 2007 Future Drugs Ltd.